Taller people are less likely to have type 2 diabetes
A new study from Germany found that taller people have a lower risk of type 2 diabetes.
The researchers searched the results to eliminate the potential effects of age, education, lifestyle, and waist size on the risk of diabetes.
They suggest that the inverse relationship between height and risk of type 2 diabetes may result from less fat accumulation in the liver and more favorable cardiometabolic risk factors such as “especially blood fats, adiponectin and C-reactive protein.”
Among those with an overweight or obese range of body mass index (BMI), the risk of type 2 diabetes decreased by 36% in men and 30% in women at every 10 cm height.
Short stature and type 2 diabetes connection
The study is a result of the work of scientists from the Center for Diabetes Research in Germany and the German Institute of Human Nutrition Potsdam-Rehbruecke.
The researchers worked on the records of 27,548 participants who participated in the European Cancer and Nutrition Survey (EPIC) survey in Potsdam, Germany between 1994-1998.
Of these participants, 16,644 are women, aged 35-65, and 10,904 are men aged 40-65. The researchers selected a sample representing 10% of the random cohort for their analysis.
The new findings also follow previous research findings linking short stature with the risk of type 2 diabetes.
It is reported that taller people may have higher insulin sensitivity and better functioning beta cells accompany these earlier findings.
These studies also found links between shorter stature and increased risk of cardiovascular conditions. Such relationships may include risk factors that have ties to type 2 diabetes, including high blood pressure, inflammation, and blood fats.
These findings suggest that it may be useful in predicting the risk of neck type 2 diabetes.
Leg length and sitting height
However, the new study not only examined the relationship between height and type 2 diabetes, but also wanted to take a closer look at two components of height height: leg length and sitting height.
The team found a strong link between long leg length for men and low risk of type 2 diabetes. However, in women, both sitting height and leg length contributed to this effect.
These findings will suggest to the authors that growth before adolescence has a more significant effect on the risk of diabetes in men than after growth. They explain this based on the assumption that the leg bones cease to grow before the trunk bones.
However, it appears that growth before and after puberty for women contributes to a reduced risk of diabetes.
Liver fat and cardiometabolic profile
The researchers calculated how much liver fat and other cardiometabolic risk factors could explain the relationship between height and type 2 diabetes among their analysis.
When they revealed the potential effect of liver fat content, a 10 cm extra height risk of type 2 diabetes in men was 34% (compared to 41% in total) and 13% in women (33). % total).
Some cardiometabolic risk factors also had an effect. In men and women, both blood fats and glycerated hemoglobin (a blood glucose measurement) appeared to affect the relationship between height and type 2 diabetes.
However, women had additional effects from adiponectin and C-reactive protein. Adiponectin is a hormone that affects blood sugar control, and C-reactive protein is a sign of inflammation.
Combining these results, the researchers suggest that much of the positive effect of higher altitude on reducing the risk of type 2 diabetes probably comes from taller people with lower liver fat content and better cardiometabolic risk profiles.
They state that their findings point to the need to include the cardiometabolic profile as well as height, as a useful predictor of the risk of diabetes.
They recommend that doctors should monitor cardiometabolic risk more frequently in short stature, even if their body size and composition indicate otherwise.
The authors conclude: “Our study also suggests that early interventions to reduce the metabolic risk associated with lifetime should focus on growth markers in sensitive periods during pregnancy, early childhood, adolescence and early adulthood, and take into account potential gender differences.”